Beyond their direct cytotoxicity, ADCs can enhance tumor immunogenicity by inducing immunogenic cell death, releasing tumor antigens and neoantigens, modulating the tumor microenvironment (e.g., reducing Tregs, upregulating PD-L1, activating cGAS–STING), and ultimately promoting CD8+ T-cell recruitment and activation [49,50,51]. The gene discussed is STING1; the disease is neoplasm.